Can’t escape ORAL Surveillance RCT talk Lots of real world data on CV risk & JAKi here (with all the selection, measurement bias) First up: multinational JAK-pot study (n=>50k) Even if you mirror the high-risk RCT cohort - not much there for MACE OP0219 #EULAR2023 @RheumNow https://t.co/FfNspdivri

No new predictors for decline in #SSc lung function in ILD Progression of #scleroderma Lung disease is common - risks male, dcSSc, low FVC, Topo1 ⁦@RheumNow⁩ #EULAR2023, OP0236 ⁦@eular_org⁩ https://t.co/bTxTyLE8dZ

An AI algorithm to predict opined related deaths UK database >1000000 pts, 1200+ opioids related deaths Risk factors: Substance used disorder Hx self harm Alcohol abuse Oxycodone Liver disease Concomitant gabapentinoids & BZD *no pictures allowed* @Rheumnow OP0269 #EULAR23 https://t.co/II96fnhqy3

JAKi use did not increase CV risk compared to TNF, no difference between Bari and Tofa, non significant increased IRR in patients >65 years, Merel Opdam, Abst#OP0221 #EULAR2023 @RheumNow https://t.co/Pu5X8RHJOY

#Deeplearning in salivary biopsies in #SjogrensSyndrome - 327 pts - binary focus score (>=1) prediction the AUROC was 0.87 and for primary sjogrens diagnosis prediction it was 0.84 Quicker and cost effective in the future? @rheumnow #EULAR2023 abst#OP0232 https://t.co/Ec0zuKqpXf

So we need protocolized extra steroids in new RA? A debate as old as time Individual patient data metaanalysis - slight gains early on, not sustained - fewer DMARD changes - but a heap more PNL, well after the protocol ends Life is about trade-offs😐 OP0220 #EULAR2023 @RheumNow https://t.co/M8SBKjGncv

#EULAR2023 #POS1066 “Diagnosis: Seropositive Nodular Rheumatoid Arthritis” - I can probably get rid of Nodular soon in my letter. Trends of Nodules have decreased over time. Could be because we are getting better at preventing erosion and smoking cessation @RheumNow https://t.co/fmQvyNHCUJ

Impact of menopause & on function in RA HAQ increases slightly after menopause Premature menopause = worse function Slightly better HAQ (but moderate & no effects on other PROs) in THR group vs. non THR No safety data @RheumNow OP0268 #EULAR23 https://t.co/7KJScF8O2X

Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w

#Scleroderma activity index #SCTC has an initial validated tool that is associated with death and organ damage with moderate correlations, so it has some degree of face validity ⁦@RheumNow⁩ #EULAR2023 ⁦@eular_org⁩ #OP0235 https://t.co/RDekhr7d2e

Initial use of glucocorticoids GC as bridging treatment in RA resulted in increase use of GC later, fewer DMARD changes later, van Ouwerkek L, Abst#OP220 #EULAR2023 @RheumNow https://t.co/IjxgQTZ8SE